Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences is viewed positively because SGT-003 appears to offer a differentiated Duchenne muscular dystrophy profile, with engineered muscle targeting, robust microdystrophin expression, nNOS restoration, and encouraging biomarker trends across CK, troponin, and LVEF. The thesis is strengthened by a notably clean safety record across 53 dosed patients, with no reported drug-induced liver injury and a simpler steroid-only prophylactic regimen that could improve adoption versus more burdensome competitor protocols. The outlook is further supported by a large untreated DMD population, a $700m EV relative to a $1b+ peak opportunity, and additional upside from SGT-212 in Friedreich’s ataxia and other cardiac programs.

Solid Biosciences is exposed to a highly uncertain gene-therapy platform where safety, immunosuppression burden, and regulatory scrutiny can quickly erode the value of its pipeline. Despite encouraging early data in 53 dosed patients, the company remains dependent on unproven programs across DMD, FA, and CPVT, while class-wide hepatotoxicity and immune-mediated adverse events have been frequent across ~2,000 patients in ~80 AAV studies. Financially, the balance sheet is not yet insulating enough, with cash, cash equivalents, investments, and available-for-sale securities of ~$236 million as of September 30, 2025, implying a need for future financing or partnerships and adding dilution risk.